Indivior's opioid treatment sales slump prompts second profit warning

Profit and Revenue Warnings: Indivior issued its second profit and revenue warning in three months, citing lower sales from its opioid addiction treatment Sublocade due to competition from Brixadi, leading to a significant drop in shares by 21.5%.

Revised Financial Outlook: The company has lowered its revenue forecast for the year to between $1.13 billion and $1.17 billion and adjusted its operating profit expectations down to $260 million to $280 million, while also facing challenges related to funding timing within the U.S. Criminal Justice System.